SOUTH SAN FRANCISCO, Calif. , Feb. 01, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation